Core Insights - Inhibikase Therapeutics, Inc. is set to report its financial results for Q2 2024 on August 14, 2024, after U.S. market close, followed by a conference call on August 15, 2024, at 8:00 a.m. ET [1] - The company focuses on developing protein kinase inhibitor therapeutics aimed at modifying the course of Parkinson's disease and related disorders [3] Company Overview - Inhibikase Therapeutics is a clinical-stage pharmaceutical company specializing in therapeutics for Parkinson's disease and related disorders, with its lead program risvodetinib targeting the treatment of Parkinson's disease [3] - The company's pipeline includes therapies for neurodegeneration, orphan indications related to Parkinson's disease, and drug delivery technologies such as IkT-001Pro, which aims to enhance patient experience with fewer side effects [3] - Inhibikase is headquartered in Atlanta, Georgia, with additional offices in Lexington, Massachusetts [3]
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024